Laura Chico

Stock Analyst at Wedbush

(0)
# 4457
Out of 5,329 analysts
245
Total ratings
28.37%
Success rate
-14.77%
Average return
46 Stocks
Name Action PT Current % Upside Ratings Updated
EWTX Edgewise Therapeutic...
Maintains: Outperform
43 43
16.71 157.33% 10 Apr 21, 2025
TRML Tourmaline Bio
Maintains: Outperform
42 43
17.89 140.36% 2 Mar 14, 2025
VIGL Vigil Neuroscience
Maintains: Outperform
24 13
2.58 403.88% 9 Mar 14, 2025
GOSS Gossamer Bio
Reiterates: Outperform
4 4
1.04 284.62% 4 Mar 14, 2025
OVID Ovid Therapeutics
Maintains: Outperform
4 3
0.32 837.5% 2 Mar 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
36 36
21.88 64.53% 6 Mar 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
27 28
5.15 443.69% 9 Mar 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
30 29
20.09 44.35% 14 Mar 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
6 6
7.5 -20% 9 Feb 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
157 147
106.71 37.76% 9 Feb 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
46 48
38.96 23.2% 12 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
16
3.66 337.16% 1 Dec 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
19 12
1.49 705.37% 10 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
30 38
23.7 60.34% 7 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
29 4
2.44 63.93% 3 Oct 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
17 25
20.81 20.13% 9 Oct 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
22
2.85 671.93% 1 Oct 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
210 205
121 69.42% 16 Sep 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
40 44
n/a n/a 7 Sep 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
40 48
38.16 25.79% 6 Aug 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
50 49
38.18 28.34% 8 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
8 7
3.58 95.53% 4 Aug 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
30 26
16.11 61.39% 7 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
11 11
5.48 100.73% 13 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
42 42
13.74 205.68% 7 Jul 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
17 17
9.88 72.06% 6 Jul 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
1435 1435
2.68 53444.78% 3 Jun 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
35 31
17.75 74.65% 5 May 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
13 11
0.31 3448.39% 4 Apr 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
5
4.75 5.26% 5 Mar 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
330
n/a n/a 6 Dec 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
n/a
n/a n/a 5 Sep 28, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
42
n/a n/a 3 Aug 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
24 5
n/a n/a 2 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
9 5
2.42 106.61% 2 Aug 12, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
149
22.56 558.24% 1 Aug 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
16
n/a n/a 1 Sep 2, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 4 Feb 8, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
33
n/a n/a 1 Sep 18, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Outperform
40
n/a n/a 3 Feb 15, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
240 0
n/a n/a 2 Sep 12, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Outperform
36 0
n/a n/a 2 Mar 2, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 2 Jan 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
720
7.54 9449.07% 1 Jan 19, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underperform
n/a
n/a n/a 1 Nov 16, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Strong Buy
280
21.81 1183.81% 1 Apr 21, 2017